Alain Ravaud

1990–2024 年に発表

114
論文数
38,835
被引用数
79
h 指数
113
i10 指数

被引用数

Alain Ravaud の年別被引用数1994 年: 被引用 1 件1995 年: 被引用 1 件1997 年: 被引用 3 件1998 年: 被引用 3 件1999 年: 被引用 14 件2000 年: 被引用 22 件2001 年: 被引用 25 件2002 年: 被引用 45 件2003 年: 被引用 48 件2004 年: 被引用 41 件2005 年: 被引用 53 件2006 年: 被引用 67 件2007 年: 被引用 86 件2008 年: 被引用 110 件2009 年: 被引用 174 件2010 年: 被引用 201 件2011 年: 被引用 219 件2012 年: 被引用 200 件2013 年: 被引用 230 件2014 年: 被引用 166 件2015 年: 被引用 162 件2016 年: 被引用 306 件2017 年: 被引用 367 件2018 年: 被引用 500 件2019 年: 被引用 1,694 件2020 年: 被引用 2,017 件2021 年: 被引用 1,708 件2022 年: 被引用 1,231 件2023 年: 被引用 896 件2024 年: 被引用 1,360 件2025 年: 被引用 558 件2026 年: 被引用 14 件1996 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,942 件、この内訳の 24%中国: 引用元論文 1,616 件、この内訳の 9.8%フランス: 引用元論文 1,102 件、この内訳の 6.7%イタリア: 引用元論文 1,001 件、この内訳の 6.1%イギリス: 引用元論文 952 件、この内訳の 5.8%ドイツ: 引用元論文 739 件、この内訳の 4.5%日本: 引用元論文 705 件、この内訳の 4.3%カナダ: 引用元論文 650 件、この内訳の 3.9%スペイン: 引用元論文 622 件、この内訳の 3.8%オランダ: 引用元論文 450 件、この内訳の 2.7%オーストラリア: 引用元論文 400 件、この内訳の 2.4%スイス: 引用元論文 382 件、この内訳の 2.3%
0%24%その他 23.7%

分野

  • Medicine77.2%
  • Biochemistry, Genetics and Molecular Biology12.8%
  • Immunology and Microbiology4%
  • Neuroscience3.9%
  • Engineering0.5%
  • Mathematics0.3%
  • その他1.3%

トピック

  • Cancer Immunotherapy and Biomarkers14%
  • Renal cell carcinoma treatment8.2%
  • Bladder and Urothelial Cancer Treatments4.9%
  • Ferroptosis and cancer prognosis3.3%
  • Immunotherapy and Immune Responses3.2%
  • CAR-T cell therapy research2.7%
  • その他63.7%

共著者

全論文

検索で開く
  1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 被引用: 4,643

  2. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 5,890

  3. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregg Fine, Thomas Powles - Nature Medicine 2018 被引用: 1,250

  4. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 525

  5. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marjorie C. Green, Robert J. Motzer - The Lancet 2019 被引用: 1,010

  6. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 1,416

  7. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2019 被引用: 571

  8. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Jing Huang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean‐Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang ほか 33 名 - The Lancet Oncology 2023 被引用: 200

  9. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2022 被引用: 190

  10. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 940

  11. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    著者: , , , , , , , , , , , , , , - The Lancet 2008 被引用: 3,012

  12. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

    著者: , , , , , , , , , , , , - Annals of Oncology 2024 被引用: 159

  13. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ali Hasbini, Guilhem Bousquet, M. Soulié - The Lancet Oncology 2013 被引用: 740

  14. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 777

  15. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    著者: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 被引用: 588

  16. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 被引用: 242

  17. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study

    著者: , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2017 被引用: 302

  18. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

    著者: , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2021 被引用: 93

  19. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort

    著者: , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2020 被引用: 82

  20. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

    著者: , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2021 被引用: 128

  21. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2020 被引用: 225

  22. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

    著者: , , , , , , , , , , , , , , - The Lancet 2007 被引用: 2,223

  23. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial

    著者: , , , , , , , , , - European Urology 2021 被引用: 121

  24. Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review

    著者: , , , , , , , , , - European Journal of Cancer 2021 被引用: 76